While in patients with EGFRm NSCLC, the predominant ctDNA use is for molecular profiling to inform clinical decision-making and for the detection of resistance mechanisms after EGFR TKIs, ctDNA is under study for monitoring molecular response to guide treatment escalation for patients with metastatic EGFR-mutant NSCLC (NCT04410796). Here, EGFR is linked to non-small cell lung carcinoma.